Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q3 FY22 results · Oct–Dec 2021
Bliss GVS Pharma reported revenue from operations of ₹216.26 crore (up 31.8% from Q3 FY21) and net loss of ₹48.53 crore for Q3 FY22 (Oct–Dec 2021), on a consolidated basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 216.26 | 164.06 | +31.8% | 195.99 | +10.3% |
| Other income | 6.04 | 4.12 | +46.7% | 5.45 | +10.8% |
| Total income | 222.29 | 168.18 | +32.2% | 201.44 | +10.4% |
| Profit before tax | (38.86) | 37.09 | Turned loss | 29.89 | Turned loss |
| Net profit for the period | (48.53) | 27.56 | Turned loss | 22.06 | Turned loss |
| Attributable to shareholders of the company | (50.11) | 25.55 | Turned loss | 21.27 | Turned loss |
| EPS, basic (₹) | (4.83) | 2.48 | Turned loss | 2.05 | Turned loss |
| Net margin (%) | -22.4 | 16.8 | 11.3 |
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 190.60 | 127.44 | +49.6% | 174.43 | +9.3% |
| Other income | 6.31 | 3.25 | +93.9% | 5.99 | +5.4% |
| Total income | 196.91 | 130.69 | +50.7% | 180.41 | +9.1% |
| Profit before tax | 36.41 | 30.44 | +19.6% | 34.77 | +4.7% |
| Net profit for the period | 27.17 | 22.46 | +21.0% | 24.73 | +9.9% |
| EPS, basic (₹) | 2.62 | 2.18 | +20.2% | 2.39 | +9.6% |
| Net margin (%) | 14.3 | 17.6 | 14.2 |
Consolidated
- Filed with BSE
- 31 Jan 2022, 08:25 IST
- Board meeting
- 29 Jan 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 31 Jan 2022, 08:25 IST
- Board meeting
- 29 Jan 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE